132 related articles for article (PubMed ID: 24378984)
21. Why patients with multiple sclerosis perceive improvement of gait during treatment with natalizumab?
Novotna K; Rusz J; Kubala Havrdova E; Lizrova Preiningerova J
J Neural Transm (Vienna); 2019 Jun; 126(6):731-737. PubMed ID: 31098724
[TBL] [Abstract][Full Text] [Related]
22. Epoch Analysis of On-Treatment Disability Progression Events over Time in the Tysabri Observational Program (TOP).
Wiendl H; Butzkueven H; Kappos L; Trojano M; Pellegrini F; Paes D; Zhang A; Belachew S;
PLoS One; 2016; 11(1):e0144834. PubMed ID: 26771747
[TBL] [Abstract][Full Text] [Related]
23. Long-term assessment of No Evidence of Disease Activity with natalizumab in relapsing multiple sclerosis.
Prosperini L; Fanelli F; Pozzilli C
J Neurol Sci; 2016 May; 364():145-7. PubMed ID: 27084235
[TBL] [Abstract][Full Text] [Related]
24. Impact of natalizumab on cognitive performances and fatigue in relapsing multiple sclerosis: a prospective, open-label, two years observational study.
Iaffaldano P; Viterbo RG; Paolicelli D; Lucchese G; Portaccio E; Goretti B; Direnzo V; D'Onghia M; Zoccolella S; Amato MP; Trojano M
PLoS One; 2012; 7(4):e35843. PubMed ID: 22558238
[TBL] [Abstract][Full Text] [Related]
25. Improvement in Cognitive Function as Measured by NeuroTrax in Patients with Relapsing Multiple Sclerosis Treated with Natalizumab: A 2-Year Retrospective Analysis.
Gudesblatt M; Wissemann K; Zarif M; Bumstead B; Fafard L; Wilken J; Blitz K; Buhse M; Santra S; Hotermans C; Lee L
CNS Drugs; 2018 Dec; 32(12):1173-1181. PubMed ID: 30143944
[TBL] [Abstract][Full Text] [Related]
26. Assessing disability progression with the Multiple Sclerosis Functional Composite.
Rudick RA; Polman CH; Cohen JA; Walton MK; Miller AE; Confavreux C; Lublin FD; Hutchinson M; O'Connor PW; Schwid SR; Balcer LJ; Lynn F; Panzara MA; Sandrock AW
Mult Scler; 2009 Aug; 15(8):984-97. PubMed ID: 19667023
[TBL] [Abstract][Full Text] [Related]
27. Natalizumab Changes the Peripheral Profile of the Th17 Panel in MS Patients: New Mechanisms of Action.
Balasa RI; Simu M; Voidazan S; Barcutean LI; Bajko Z; Hutanu A; Simu I; Maier S
CNS Neurol Disord Drug Targets; 2017; 16(9):1018-1026. PubMed ID: 28782487
[TBL] [Abstract][Full Text] [Related]
28. Natalizumab for the prevention of post-partum relapses in women with multiple sclerosis.
Vukusic S; Durand-Dubief F; Benoit A; Marignier R; Frangoulis B; Confavreux C
Mult Scler; 2015 Jun; 21(7):953-5. PubMed ID: 25305253
[TBL] [Abstract][Full Text] [Related]
29. Erythroblastaemia in natalizumab-treated patients with multiple sclerosis.
La Gioia S; Seghezzi M; Barcella V; Dominoni P; Mecca T; Frigeni B; Conti MZ; Vedovello M; Vidali M; Rottoli M; Buoro S
Mult Scler Relat Disord; 2016 Jul; 8():141-4. PubMed ID: 27456890
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of natalizumab in second line therapy of relapsing-remitting multiple sclerosis: results from a multi-center study in German speaking countries.
Putzki N; Yaldizli O; Mäurer M; Cursiefen S; Kuckert S; Klawe C; Maschke M; Tettenborn B; Limmroth V
Eur J Neurol; 2010 Jan; 17(1):31-7. PubMed ID: 19614963
[TBL] [Abstract][Full Text] [Related]
31. Natalizumab reduces relapse clinical severity and improves relapse recovery in MS.
Lublin FD; Cutter G; Giovannoni G; Pace A; Campbell NR; Belachew S
Mult Scler Relat Disord; 2014 Nov; 3(6):705-11. PubMed ID: 25891549
[TBL] [Abstract][Full Text] [Related]
32. Improvements in Cognitive Processing Speed, Disability, and Patient-Reported Outcomes in Patients with Early Relapsing-Remitting Multiple Sclerosis Treated with Natalizumab: Results of a 4-year, Real-World, Open-Label Study.
Perumal J; Balabanov R; Su R; Chang R; Balcer LJ; Galetta SL; Avila RL; Rutledge D; Fox RJ
CNS Drugs; 2022 Sep; 36(9):977-993. PubMed ID: 36064841
[TBL] [Abstract][Full Text] [Related]
33. Changes in brain atrophy indices in patients with relapsing-remitting multiple sclerosis treated with natalizumab.
Arpín EC; Sobrino TG; Vivero CD; del Campo Amigo Jorrín M; Regal AR; González JP; Bouzas ML
Neurodegener Dis Manag; 2016; 6(1):5-12. PubMed ID: 26782312
[TBL] [Abstract][Full Text] [Related]
34. Association between soluble L-selectin and anti-JCV antibodies in natalizumab-treated relapsing-remitting MS patients.
Basnyat P; Hagman S; Kolasa M; Koivisto K; Verkkoniemi-Ahola A; Airas L; Elovaara I
Mult Scler Relat Disord; 2015 Jul; 4(4):334-8. PubMed ID: 26195052
[TBL] [Abstract][Full Text] [Related]
35. Lymphocytosis as a response biomarker of natalizumab therapeutic efficacy in multiple sclerosis.
Signoriello E; Lanzillo R; Brescia Morra V; Di Iorio G; Fratta M; Carotenuto A; Lus G
Mult Scler; 2016 Jun; 22(7):921-5. PubMed ID: 26453682
[TBL] [Abstract][Full Text] [Related]
36. Short-term impact of fampridine on motor and cognitive functions, mood and quality of life among multiple sclerosis patients.
Pavsic K; Pelicon K; Ledinek AH; Sega S
Clin Neurol Neurosurg; 2015 Dec; 139():35-40. PubMed ID: 26363365
[TBL] [Abstract][Full Text] [Related]
37. Relapses in patients treated with fingolimod after previous exposure to natalizumab.
Comi G; Gold R; Dahlke F; Sinha A; von Rosenstiel P; Tomic D; Kappos L
Mult Scler; 2015 May; 21(6):786-90. PubMed ID: 25257618
[TBL] [Abstract][Full Text] [Related]
38. Smoking is associated with increased disease activity during natalizumab treatment in multiple sclerosis.
Petersen ER; Søndergaard HB; Laursen JH; Olsson AG; Börnsen L; Soelberg Sørensen P; Sellebjerg F; Bang Oturai A
Mult Scler; 2019 Aug; 25(9):1298-1305. PubMed ID: 30070595
[TBL] [Abstract][Full Text] [Related]
39. Natalizumab vs interferon beta 1a in relapsing-remitting multiple sclerosis: a head-to-head retrospective study.
Lanzillo R; Quarantelli M; Bonavita S; Ventrella G; Lus G; Vacca G; Prinster A; Orefice G; Tedeschi G; Brescia Morra V
Acta Neurol Scand; 2012 Nov; 126(5):306-14. PubMed ID: 22107083
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of the effectiveness of home based or hospital based calisthenic exercises in patients with multiple sclerosis.
Aydın T; Akif Sarıyıldız M; Guler M; Celebi A; Seyithanoglu H; Mirzayev I; Peru C; Sezer E; Batmaz I
Eur Rev Med Pharmacol Sci; 2014; 18(8):1189-98. PubMed ID: 24817294
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
